Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Atkinson

Showing results (1481-1490 of 1,523) with videos related to

Pageof 153
Sort By:
ACS Medicinal Chemistry Letters|August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) FamilyAlex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Cancers|December 10, 2021
CHFR and Paclitaxel Sensitivity of Ovarian CancerAndrea E Wahner Hendrickson, Daniel W Visscher, Xiaonan Hou, et al.
Annals of the American Thoracic Society|September 13, 2013
Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesiaMargaret W Leigh, Milan J Hazucha, Kunal K Chawla, et al.
Nature Communications|February 24, 2017
Cellular senescence mediates fibrotic pulmonary diseaseMarissa J Schafer, Thomas A White, Koji Iijima, et al.
Circulation. Genomic and Precision Medicine|February 25, 2021
Conserved Role of the Large Conductance Calcium-Activated Potassium Channel, K<sub>Ca</sub>1.1, in Sinus Node Function and Arrhythmia RiskSantiago Pineda, Vesna Nikolova-Krstevski, Christiana Leimena, et al.
Journal of Medicinal Chemistry|July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) InhibitorJonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 19, 2025
Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinomaXiaonan Hou, Valentina Zanfagnin, Conway Xu, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activityPeter J Atkinson, Steven M Bromidge, Mark S Duxon, et al.
Journal of the National Cancer Institute|May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsM J Piccart, K Bertelsen, K James, et al.
Nature Communications|June 6, 2024
Single-cell transcriptomic atlas reveals increased regeneration in diseased human inner ear balance organsTian Wang, Angela H Ling, Sara E Billings, et al.
Pageof 153

Showing results (1481-1490 of 1,523) with videos related to

Sort By:
Pageof 153
ACS Medicinal Chemistry Letters|August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) FamilyAlex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Cancers|December 10, 2021
CHFR and Paclitaxel Sensitivity of Ovarian CancerAndrea E Wahner Hendrickson, Daniel W Visscher, Xiaonan Hou, et al.
Annals of the American Thoracic Society|September 13, 2013
Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesiaMargaret W Leigh, Milan J Hazucha, Kunal K Chawla, et al.
Nature Communications|February 24, 2017
Cellular senescence mediates fibrotic pulmonary diseaseMarissa J Schafer, Thomas A White, Koji Iijima, et al.
Circulation. Genomic and Precision Medicine|February 25, 2021
Conserved Role of the Large Conductance Calcium-Activated Potassium Channel, K<sub>Ca</sub>1.1, in Sinus Node Function and Arrhythmia RiskSantiago Pineda, Vesna Nikolova-Krstevski, Christiana Leimena, et al.
Journal of Medicinal Chemistry|July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) InhibitorJonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 19, 2025
Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinomaXiaonan Hou, Valentina Zanfagnin, Conway Xu, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activityPeter J Atkinson, Steven M Bromidge, Mark S Duxon, et al.
Journal of the National Cancer Institute|May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsM J Piccart, K Bertelsen, K James, et al.
Nature Communications|June 6, 2024
Single-cell transcriptomic atlas reveals increased regeneration in diseased human inner ear balance organsTian Wang, Angela H Ling, Sara E Billings, et al.
Pageof 153